Mirae Asset Global Investments Co., Ltd. Avidity Biosciences, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $22.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,236 shares of RNA stock, worth $129,198. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,236
Previous 2,855
48.37%
Holding current value
$129,198
Previous $116,000
67.24%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding RNA
# of Institutions
255Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$324 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$281 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$263 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$248 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$214 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.59B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...